Combining Rosetta Genomics know-how and proprietary technologies with Columbia University Medical Center’s expertise in cancer, researchers are expected to screen for microRNAs that may be used as potential biomarkers and drug targets for these non-Hodgkin lymphoma indications.
Amir Avniel, president and CEO of Rosetta Genomics, said: “We are constantly expanding our pipeline with new diagnostic and therapeutic programs, both cancer and non-cancer related, in order to maximize our leading position in microRNA intellectual property and proprietary technologies. We are very excited to be collaborating with a leading research institution such as Columbia University Medical Center, and hope more collaboration will follow.”